Background: A wide excision is generally accepted to be the standard modality of treatment for scrotal extramammary Paget’s disease (EMPD). The disease has a recurrence rate of about 10% and a second wide excision is still the chief treatment. We investigated the therapeutic methods for recurrent scrotal EMPD. Methods: We retrospectively studied the therapeutic methods and prognosis of 26 cases of recurrent EMPD. Seventy-two cases of primary scrotal EMPD served as controls. All of the cases were treated with frozen section-guided wide local excision. Results: There was no significant difference in the follow-up period of the recurrent cases before recurrence (p = 0.3228), local recurrence rate (p = 0.449), and total recurrence rate (p = 0.100) between the two groups, respectively. There is a favorable trend of worse mortality rate in the recurrence group (p = 0.056). The rate of inguinal lymph node metastasis was higher in the group with recurrent disease than in the control group (p = 0.017). Conclusion: Wide excision of the lesion still appears to be the most effective modality of treatment for recurrent scrotal Paget’s disease. Inguinal lymphadenectomy or sentinel lymph node biopsy should be offered to patients with primary lesions.

Paget J: On disease of the mammary areola preceding cancer of the mammary gland. St Bartholomew Hosp Rep 1874;10:87–89.
Li B, Ding Q: Extramammary Paget’s disease involving the penis, scrotum and the axilla. Australas J Dermatol 2011;52:e18–e20.
Chagpar AB, Heim K, Carron KR, Sewell C: Paget’s disease of the axilla: an unusual case. Breast J 2007;13:291–293.
Xu K, Fang Z, Zheng J, Lu Y, Li B, Sun C, Ding Q: Intraoperative frozen biopsy in wide surgical excision of Paget’s disease of the scrotum. Urol Oncol 2009;27:483–485.
Zhu Y, Ye DW, Chen ZW, Zhang SL, Qin XJ: Frozen section-guided wide local excision in the treatment of penoscrotal extramammary Paget’s disease. BJU Int 2007;100:1282–1287.
Wang Z, Lu M, Dong GQ, Jiang YQ, Lin MS, Cai ZK, Ying J, Ren X, Liu B: Penile and scrotal Paget’s disease: 130 Chinese patients with long-term follow-up. BJU Int 2008;102:485–488.
Ray B, Whitmore WF Jr: Experience with carcinoma of the scrotum. J Urol 1977;117:741–745.
Yang WJ, Kim DS, Im YJ, Cho KS, Rha KH, Cho NH, Choi YD: Extramammary Paget’s disease of penis and scrotum. Urology 2005;65:972–975.
Hendi A, Brodland DG, Zitelli JA: Extramammary Paget’s disease: surgical treatment with Mohs micrographic surgery. J Am Acad Dermatol 2004;51:767–773.
Lee KY, Roh MR, Chung WG, Chung KY: Comparison of Mohs micrographic surgery and wide excision for extramammary Paget’s disease: Korean experience. Dermatol Surg 2009;35:34–40.
Hata M, Omura M, Koike I, Wada H, Miyagi E, Tayama Y, Odagiri K, Minagawa Y, Ogino I, Inoue T: Role of radiotherapy as curative treatment of extramammary Paget’s disease. Int J Radiat Oncol Biol Phys 2011;80:47–54.
Cohen PR, Schulze KE, Tschen JA, Hetherington GW, Nelson BR: Treatment of extramammary Paget disease with topical imiquimod cream: case report and literature review. South Med J 2006;99:396–402.
Li L, Deng Y, Zhang L, Liao W, Luo R, Huang Z: Treatment of perianal Paget’s disease using photodynamic therapy with assistance of fluorescence examination: case report. Lasers Med Sci 2009;24:981–984.
Torchia D, Cappugi P: Intralesional photodynamic therapy: a comment on ‘Pretreatment to enhance protoporphyrin IX accumulation in photodynamic therapy’ by Gerritsen et al. Dermatology 2010;220:44–45.
Tonguc E, Güngor T, Var T, Ozat M, Sahin I, Sirvan L: Treatment of recurrent vulvar Paget disease with imiquimod cream: a case report and review of the literature. Arch Gynecol Obstet 2011;283:97–101.
Ho SA, Aw DC: Extramammary Paget’s disease treated with topical imiquimod 5% cream. Dermatol Ther 2010;23:423–427.
Dias Coelho J, Vale E, Viana I, Martins O: Treatment of primary extramammary Paget’s disease of the perineum with topical imiquimod 5% cream. Eur J Dermatol 2010;20:532–533.
Zhu Y, Ye DW, Yao XD, Zhang SL, Dai B, Zhang HL, Shen YJ, Mao HR: Clinicopathological characteristics, management and outcome of metastatic penoscrotal extramammary Paget’s disease. Br J Dermatol 2009;161:577–582.
Takahagi S, Noda H, Kamegashira A, Madokoro N, Hori I, Shindo H, Mihara S, Hide M: Metastatic extramammary Paget’s disease treated with paclitaxel and trastuzumab combination chemotherapy. J Dermatol 2009;36:457–461.
Li YC, Lu LY, Yang YT, Chang CC, Chen LM: Extramammary Paget’s disease of the scrotum associated with hepatocellular carcinoma. J Chin Med Assoc 2009;72:542–546.
Lai YL, Yang WG, Tsay PK, Swei H, Chuang SS, Wen CJ: Penoscrotal extramammary Paget’s disease: a review of 33 cases in a 20-year experience. Plast Reconstr Surg 2003;112:1017–1023.
Tsutsumida A, Yamamoto Y, Minakawa H, Yoshida T, Kokubu I, Sugihara T: Indications for lymph node dissection in the treatment of extramammary Paget’s disease. Dermatol Surg 2003;29:21–24.
Yoshino K, Yamazaki N, Yamamoto A, Namikawa K, Abe M, Yoshida H: On the TNM classification of extramammary Paget’s disease. Jpn J Dermatol 2006;116:1313–1318.
Blum A, Schmid-Wendtner MH, Mauss-Kiefer V, Eberle JY, Kuchelmeister C, Dill-Müller D: Ultrasound mapping of lymph node and subcutaneous metastases in patients with cutaneous melanoma: results of a prospective multicenter study. Dermatology 2006;212:47–52.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.